LENZ Therapeutics (LENZ) Set to Announce Quarterly Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) is set to release its earnings data after the market closes on Wednesday, May 8th. Analysts expect LENZ Therapeutics to post earnings of ($0.84) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

LENZ Therapeutics Price Performance

Shares of NASDAQ:LENZ traded up $0.12 during trading on Tuesday, hitting $16.30. 100,843 shares of the stock were exchanged, compared to its average volume of 77,230. LENZ Therapeutics has a 1-year low of $14.07 and a 1-year high of $29.82.

Insider Transactions at LENZ Therapeutics

In other news, Director Ra Capital Management, L.P. acquired 998,009 shares of LENZ Therapeutics stock in a transaction that occurred on Thursday, March 21st. The shares were acquired at an average price of $15.03 per share, with a total value of $15,000,075.27. Following the purchase, the director now directly owns 3,319,339 shares of the company’s stock, valued at $49,889,665.17. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 38.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on LENZ shares. Citigroup began coverage on shares of LENZ Therapeutics in a report on Wednesday, April 10th. They set a “buy” rating and a $34.00 price objective for the company. Piper Sandler assumed coverage on shares of LENZ Therapeutics in a research note on Wednesday, March 27th. They set an “overweight” rating and a $28.00 price target for the company. William Blair initiated coverage on LENZ Therapeutics in a report on Monday, April 15th. They issued an “outperform” rating for the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of LENZ Therapeutics in a research note on Monday, April 15th. Finally, SVB Leerink began coverage on LENZ Therapeutics in a report on Monday, April 15th. They issued an “outperform” rating and a $32.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $31.33.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.